Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

lue; 1,000 million shares authorized; and 562.5 million shares issued and outstanding (2010: 1,000 million shares authorized; and 562.2 million shares issued and outstanding) 55.7 55.7 Additional paid-in capital 2,824.5 2,746.4 Treasury stock: 12.5 million shares (2010: 14.0 million) (293.1) (276.1) Accumulated other comprehensive income 88.5 85.7 Retained earnings/(accumulated deficit) 279.1 (160.3) Total equity 2,954.7 2,451.4 Total liabilities and equity 6,065.6 5,387.6

Unaudited US GAAP results for the three months and nine months to September 30, 2011
Consolidated Statements of Income

9 months 3 months to 3 months to 9 months to to September September September September 30, 30, 30, 30, 2011 2010 2011 2010 $M $M $M $M Revenues: Product sales 1,018.4 794.3 2,901.0 2,276.8 Royalties 62.8 76.5 199.8 254.5 Other revenues 4.9 3.5 20.4 8.6 Total revenues 1,086.1 874.3 3,121.2 2,539.9 Costs and expenses: Cost of product sales(1) 166.5 112.7 434.7 333.7 Research and development(1) 201.5 197.9 556.3 475.9 Selling, general and administrative(1) 452.1 392.4 1,295.3 1,106.7 Loss/(gain) on sale of product rights 0.3 - 3.8 (4.1) Reorganization costs 5.0 9.7 18.0 23.3 Integration and acquisition costs 5.3 5.8 7.9 6.4 Total operating expenses 830.7 718.5 2,316.0 1,941.9 Operating income 255.4 155.8 805.2 598.0 Interest income 0.3 1.0 1.5 1.9 Interest expense (9.7) (8.3) (28.8) (25.6) Other income, net 15.6 0.8 15.9 9.0 Total other income/(expense), net 6.2 (6.5) (11.4) (14.7) Income before income taxes and equity in earnings/(losses) of equity method investees 261.6 149.3 793.8 583.3 Income taxes (69.5) (52.7) (187.3) (160.8) Equity in earnings/(losses) of equity method investees, net of taxes 0.8 (0.3) 3.2 0.2 Net income 192.9 96.3 609.7 422.7

(1) Cost of product sales includes amortization of intangible assets relating to favorable manufacturing contracts of $0.5 million f
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... The report expects global cell isolation and expansion ... provides a carefully analyzed data about the vital drivers, ... , Full Copy of Report @ http://bit.ly/1yUxy0T ... cell expansion will keep witnessing growth at an impressive ... be driven by rapid technological advancements, government funding and ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... free Importance of Mixing webinar will compare lab mixing and large ... Reinaldo M. Machado entitled "Fundamentals of Scale-up" and "iControl Mixing Guidelines". ... ... METTLER TOLEDO invites you to view a free on-demand webinar ...
... Cytopia Limited (ASX: CYT) announced that it will present ... at the forthcoming 100th Annual Meeting of the American ... David Segal, Principal Scientist at Cytopia, will be presenting ... Molecular Therapeutics 2 poster session on Tuesday, April ...
... China, April 15 /PRNewswire-Asia-FirstCall/ -- China Sky One,Medical, Inc. ... CSKI ), a,leading fully integrated pharmaceutical company producing ... announced that it will,conduct a conference call at 10:00 ... to discuss its fourth quarter and fiscal year 2008,financial ...
Cached Biology Technology:The Importance of Mixing: How to Compare Lab Scale Mixing with Full Scale Process Vessel Performance 2Cytopia Presentation on VDA CYT997 at AACR Conference 2China Sky One Medical, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2008 Results 2
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
(Date:11/21/2014)... SAN JOSE, Calif. , Nov. 20, 2014 /PRNewswire/ ... a global leader in microcontroller (MCU) and touch technology ... digital temperature sensors with the widest V ... family delivers higher temperature accuracy and faster I 2 ... nonvolatile registers and serial EEPROM memory making them ideal ...
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... CSIRO researchers, in collaboration with the International Maize ... the research illustrates the major genetic improvements possible ... often use wild relatives of wheat as sources ... research team leader Dr Phil Larkin says. ...
... Growth hormone treatments work better on some children than on ... in height is no simple task. Now researchers have developed ... growth hormone to treat children who are abnormally short for ... the online open access journal BMC Medical Informatics and Decision ...
... the University of Southern California (USC) suggest epigenetics, or the ... cause for male infertility. The study will be published in ... This is the first report based on our ... semen development, says Rebecca Sokol, M.D., MPH, professor of obstetrics ...
Cached Biology News:Building disease-beating wheat 2USC researchers explore genetic causes for male infertility 2
... Nonanoyl-N-methylglucamide White ... Can be readily removed by dialysis. ... Purity: ≥98% by HPLC. Absorbance ... 2 O. CMC 19 - ...
...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
... polyclonal to HDAC4 - ChIP Grade ... II mammalian histone deacetylases, which consists of ... is highly similar to the deacetylase domain ... shuttles between the nucleus and cytoplasm in ...
Biology Products: